Aurobindo Pharma Gets 3 Observations From USFDA For Its Medchal Unit
The Indian pharma major Aurobindo Pharma on Friday stated in an exchange filing that the United States Food and Drug Administration (US FDA) inspected its Unit III, a formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana, from 14th July to 21st July 2023.
The company said that at the end of the inspection, USFDA issued a ‘Form 483’ with 3 observations. Calling the observations procedural in nature the company said it will respond to USFDA within given time.
"The observations are procedural in nature. We will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observations at the earliest," the company said in a statement.
On Monday the company's stock revived and closed at 0.74 per cent higher at Rs 785.15 after falling on Friday and closing at Rs 779.40.
